13.2 Refeeding Syndrome and Complications of Parenteral Nutrition

Two dangerous complications of nutrition support are tested repeatedly: refeeding syndrome, which can occur with oral, enteral, or parenteral feeding, and the long-term complications of parenteral nutrition.

Refeeding Syndrome: Molecular Pathophysiology & Prevention Protocols

Refeeding Syndrome is a potentially lethal constellation of metabolic and electrolyte derangements that occurs when nutritional support (carbohydrate calories via oral, enteral, or parenteral routes) is introduced too rapidly in severely malnourished, cachectic, or starved patients.

                      Prolonged Starvation / Chronic Malnutrition
                       - Depleted glycogen, shifted to fat/ketones
                       - Low basal insulin, elevated glucagon
                       - Total-body electrolyte depletion (P, K, Mg)
                                     │
                                     ▼
                      RAPID CARBOHYDRATE REINTRODUCTION
                                     │
                                     ▼
                     MASSIVE ENDOGENOUS INSULIN SURGE
                                     │
        ┌────────────────────────────┼────────────────────────────┐
        ▼                            ▼                            ▼
[Electrolyte Shift]          [Thiamine Depletion]         [Renal Na+ Retention]
- Rapid cellular uptake of   - TPP exhausted by sudden    - Insulin stimulates renal
  Phosphate, Potassium,        carbohydrate glycolysis      sodium reabsorption
  and Magnesium              - Pyruvate cannot form       - Extracellular fluid expansion
        │                      Acetyl-CoA                   Pulmonary edema
        ▼                    - Severe Lactic Acidosis       Congestive heart failure
Severe Hypophosphatemia        Wernicke Encephalopathy
Severe Hypokalemia           - Wet Beriberi
Severe Hypomagnesemia
        │
        ▼
Cardiac Arrhythmias (Torsades de pointes, VFib)
Respiratory Diaphragmatic Paralysis (ATP exhaustion)
Rhabdomyolysis, Seizures, Sudden Cardiopulmonary Death

The Molecular Mechanism

1. Starvation Physiology: During prolonged starvation, insulin secretion drops markedly, while glucagon and catecholamines rise. The body downregulates glycolysis and depends on fatty acid oxidation and ketone bodies for energy. While serum electrolyte concentrations (phosphate, potassium, magnesium) may appear normal in baseline blood draws due to hemoconcentration and intracellular extrusion, total body intracellular stores are severely depleted.
2. The Insulin Spike: When carbohydrates (dextrose) are reintroduced, blood glucose levels rise, prompting the pancreatic $\beta$-cells to secrete a massive surge of insulin.
3. Intracellular Shift of Electrolytes: Insulin stimulates the cell membrane $Na^+/K^+$ ATPase pump and initiates protein, glycogen, and fat synthesis. These anabolic pathways drive a massive, rapid influx of phosphate, potassium, magnesium, and water from the extracellular fluid into the intracellular compartment.
4. The Cascade of Clinical Disasters:
   • Severe Hypophosphatemia ($<1.0\text{ mg/dL}$ / $<0.3\text{ mmol/L}$): The undisputed hallmark of refeeding syndrome. Intracellular glucose phosphorylation rapidly consumes remaining inorganic phosphate, depleting Adenosine Triphosphate (ATP) and 2,3-Diphosphoglycerate (2,3-DPG) in red blood cells. Loss of 2,3-DPG shifts the oxyhemoglobin dissociation curve to the left, impairing oxygen release to tissues. ATP depletion results in acute diaphragmatic paralysis, respiratory failure, inability to wean from mechanical ventilation, impaired cardiac contractility, acute congestive heart failure, rhabdomyolysis, paresthesias, seizures, and death.
   • Severe Hypokalemia ($<3.0\text{ mEq/L}$): Massive potassium uptake into cells causes severe hypokalemia, inducing lethal ventricular arrhythmias (ventricular tachycardia, fibrillation, asystole), paralytic ileus, and muscle flaccidity.
   • Severe Hypomagnesemia ($<1.2\text{ mg/dL}$): Magnesium is a necessary cofactor for the $Na^+/K^+$ ATPase pump and hundreds of metabolic enzymes. Hypomagnesemia triggers cardiac dysrhythmias (Torsades de pointes), neuromuscular tremors, tetany, and refractory hypokalemia and hypocalcemia.
   • Acute Thiamine (Vitamin $B_1$) Depletion: Thiamine pyrophosphate (TPP) is an indispensable cofactor for pyruvate dehydrogenase (converting pyruvate to acetyl-CoA) and transketolase. The sudden carbohydrate load overwhelms minimal residual thiamine stores. Inability to metabolize pyruvate forces conversion to lactate, triggering severe lactic acidosis, acute Wernicke encephalopathy (mental confusion, ataxia, ophthalmoplegia/nystagmus), and wet beriberi (acute high-output heart failure).
   • Sodium Retention and Fluid Overload: Insulin acts directly on renal distal convoluted tubules, stimulating sodium reabsorption. Fluid follows sodium, expanding extracellular volume and precipitating acute pulmonary edema and biventricular heart failure.

Clinical Criteria for High Risk of Refeeding Syndrome (NICE Guidelines)

High-Risk Clinical Populations: Chronic alcoholism, anorexia nervosa, oncology cachexia, morbidly obese patients with massive rapid weight loss (post-bariatric surgery), elderly living alone with protracted malnutrition, chronic malabsorptive states (celiac, Crohn's), and post-op surgical patients kept NPO for $>7–10$ days on unsupplemented IV fluids (D5W).

Evidence-Based Prevention and Management Protocol

                    PATIENT AT HIGH RISK OF REFEEDING
                                    │
                                    ▼
                 [STEP 1: PRE-FEEDING ELECTROLYTE CORRECTION]
                  Check baseline serum Phosphate, K+, Mg++, Ca++
                  AGGRESSIVELY CORRECT DEFICITS BEFORE FEEDING
                                    │
                                    ▼
                 [STEP 2: PROPHYLACTIC THIAMINE ADMINISTRATION]
                  Administer Thiamine 100–300 mg/day IV or oral
                  PLUS balanced multivitamin BEFORE ANY CALORIES!
                  Continue daily for at least 3 to 5 days
                                    │
                                    ▼
                 [STEP 3: 'START LOW AND ADVANCE SLOW']
                  Initiate feeding at 10 to 15 kcal/kg/day
                  (or <= 50% of estimated resting requirements)
                  Extreme risk (BMI < 14): start at 5–10 kcal/kg/day
                  Limit dextrose: <= 100–150 g/day (GIR <= 1.5–2.0)
                                    │
                                    ▼
                 [STEP 4: INTENSIVE ELECTROLYTE SURVEILLANCE]
                  Monitor serum Phosphate, K+, Mg++ daily for 7 days
                  Re-supplement electrolytes aggressively
                  Restrict sodium (<1 mEq/kg/day) to prevent edema
                                    │
                                    ▼
                 [STEP 5: GRADUAL CALORIC ADVANCEMENT]
                  Advance calories by 200–300 kcal/day every 1–2 days
                  ONLY IF electrolytes remain completely stable
                  Reach full nutritional target by Day 4 to Day 7

---

PN Complications and Metabolic Monitoring Protocols

1. Infectious Complications: Catheter-Related Bloodstream Infections (CRBSI)

• Etiology: CRBSI is the most common severe infectious hazard in parenteral nutrition support. Major pathogens include Staphylococcus epidermidis (coagulase-negative staph), Staphylococcus aureus, Candida albicans, and enteric gram-negative bacilli.
• Prevention Protocols: Strict aseptic insertion technique using chlorhexidine gluconate skin antisepsis; full sterile barrier precautions (sterile gown, gloves, mask, cap, large full-body drape); transparent semipermeable dressing over exit site.
• The Dedicated PN Lumen Rule: A central catheter lumen designated for PN must be strictly dedicated to parenteral nutrition. Never draw blood, administer IV push medications, piggyback antibiotics, or measure Central Venous Pressure (CVP) through the PN line!

2. Hepatobiliary Complications: PNALD and Cholestasis

Parenteral Nutrition-Associated Liver Disease (PNALD) encompasses a clinical spectrum that can progress to end-stage cirrhosis:

• Hepatic Steatosis: Occurs early, presenting with mild-to-moderate elevations in ALT and AST. Driven primarily by caloric overfeeding and excessive glucose infusion rates ($GIR > 5\text{ mg/kg/min}$) driving de novo lipogenesis.
• Cholestasis: Occurs with prolonged PN ($>2\text{ to }4\text{ weeks}$), characterized by progressive elevations in direct (conjugated) bilirubin, alkaline phosphatase, and GGT. Driven by lack of enteral stimulation (absence of CCK release leads to biliary stasis and gallbladder sludge/cholelithiasis) and toxicity from phytosterols present in 100% soybean-based IVLE.
• Prevention and Management:
  • Avoid total caloric overfeeding; maintain GIR $<4\text{ to }5\text{ mg/kg/min}$.
  • Cycle PN Infusions: Transition from continuous 24-hour infusion to cyclic infusion over 12 to 16 hours daily. An 8-to-12-hour "PN-free window" allows serum insulin levels to drop, promoting hepatic glycogen and lipid mobilization.
  • Switch from 100% soybean IVLE to multi-oil SMOF lipid emulsions containing fish oil.
  • Initiate Trophic Enteral Feeds: Administer even minimal enteral formula ($10\text{ to }20\text{ mL/hr}$) to stimulate duodenal CCK release, promoting gallbladder contraction and bile flow.

3. Metabolic Bone Disease

Long-term PN therapy ($>3\text{ months}$) can induce osteopenia, osteoporosis, or osteomalacia. Etiological factors include chronic hypercalciuria (induced by high-protein amino acid loads), chronic metabolic acidosis, vitamin D deficiency/toxicity, and trace aluminum contamination from calcium/phosphate salt compounding vials. Management involves monitoring DXA bone scans, minimizing excessive amino acid loads, and correcting hypercalciuria.

4. Glycemic Instability and Discontinuation Protocols

• Hyperglycemia ($>180\text{ mg/dL}$): Increases susceptibility to CRBSI, induces osmotic diuresis, and exacerbates systemic inflammation. Manage by adding regular human insulin directly into the PN admixture (starting at $0.1\text{ to }0.2\text{ units per gram of dextrose}$) or utilizing an external IV insulin infusion.
• Rebound Hypoglycemia: Abrupt cessation of a hypertonic dextrose PN infusion leaves circulating endogenous insulin levels high, causing a rapid plunge in plasma glucose.
• Safe Discontinuation Protocol:
  • Taper the infusion rate by $50\%$ for 1 to 2 hours prior to stopping.
  • If a central line is lost unexpectedly or a PN bag runs dry, immediately hang $10\%$ Dextrose in Water (D10W) at the same infusion rate to prevent rebound hypoglycemia.
• Transitioning from PN to Enteral/Oral Nutrition:
  • Introduce trophic enteral feeds as soon as bowel motility returns.
  • When enteral or oral feeds reach $\ge 60\%$ of estimated caloric and protein needs, taper the PN infusion rate by 50%.
  • Completely discontinue PN when enteral or oral intake reliably matches $\ge 75\%\text{ to }80\%$ of total nutritional requirements across 48 consecutive hours.